Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors

International Journal of Molecular Sciences

Volumn 13, Issue 11, 2012, Pages 13949-13965

  Yeom, Chan Joo ^a   Goto, Yoko ^a,b   Zhu, Yuxi ^a,b,c   Hiraoka, Masahiro ^b   Harada, Hiroshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Glucose availability; Hypoxia; Hypoxia inducible factor 1 (HIF 1); Metabolism; Radioresistance; Tumor microenvironment

Indexed keywords

GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

CANCER CELL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL CYCLE PROGRESSION; CELL PH; CELL POPULATION; CELL PROLIFERATION; GLUCOSE METABOLISM; HUMAN; NONHUMAN; OXYGEN CONCENTRATION; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TUMOR MICROENVIRONMENT; ANIMAL; ANOXIA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; OXYGEN CONSUMPTION; PATHOLOGY; RADIATION DOSE;

ANIMALS; ANOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; OXYGEN CONSUMPTION; RADIATION TOLERANCE; TUMOR MICROENVIRONMENT;

EID: 84870682313     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131113949     Document Type: Review

References (82)

1. Kizaka-Kondoh, S.; Inoue, M.; Harada, H.; Hiraoka, M. Tumor hypoxia: A target for selective cancer therapy. Cancer Sci. 2003, 94, 1021-1028.
2. Thomlinson, R.H.; Gray, L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 1955, 9, 539-549.
3. Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92, 5510-5514.
4. Berra, E.; Roux, D.; Richard, D.E.; Pouyssegur, J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: Nucleus or cytoplasm. EMBO Rep. 2001, 2, 615-620.
5. Jaakkola, P.; Mole, D.R.; Tian, Y.M.; Wilson, M.I.; Gielbert, J.; Gaskell, S.J.; Kriegsheim, A.; Hebestreit, H.F.; Mukherji, M.; Schofield, C.J.; et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
6. Semenza, G.L. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 2009, 19, 12-16.
7. Chan, D.A.; Giaccia, A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007, 26, 333-339.
8. Sullivan, R.; Graham, C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007, 26, 319-331.
9. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16, 4604-4613.
10. Liao, D.; Johnson, R.S. Hypoxia: A key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26, 281-290.
11. Deschner, E.E.; Gray, L.H. Influence of oxygen tension on X-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo. Radiat Res. 1959, 11, 115-146.
12. Gray, L.H.; Conger, A.D.; Ebert, M.; Hornsey, S.; Scott, O.C. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. 1953, 26, 638-648.
13. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989, 49, 6449-6465.
14. Harrison, L.B.; Chadha, M.; Hill, R.J.; Hu, K.; Shasha, D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7, 492-508.
15. Gorski, D.H.; Beckett, M.A.; Jaskowiak, N.T.; Calvin, D.P.; Mauceri, H.J.; Salloum, R.M.; Seetharam, S.; Koons, A.; Hari, D.M.; Kufe, D.W.; et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999, 59, 3374-3378.
16. Harada, H. How can we overcome tumor hypoxia in radiation therapy? J. Radiat. Res. (Tokyo) 2011, 52, 545-556.
17. Harada, H.; Hiraoka, M. Hypoxia-inducible factor 1 in tumor radioresistance. Curr. Signal Transduction Ther. 2010, 5, 188-196.
18. Harada, H.; Kizaka-Kondoh, S.; Li, G.; Itasaka, S.; Shibuya, K.; Inoue, M.; Hiraoka, M. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 2007, 26, 7508-7516.
19. Moeller, B.J.; Cao, Y.; Li, C.Y.; Dewhirst, M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004, 5, 429-441.
20. Moeller, B.J.; Dewhirst, M.W. Raising the bar: How HIF-1 helps determine tumor radiosensitivity. Cell. Cycle 2004, 3, 1107-1110.
21. Aebersold, D.M.; Burri, P.; Beer, K.T.; Laissue, J.; Djonov, V.; Greiner, R.H.; Semenza, G.L. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61, 2911-2916.
22. Irie, N.; Matsuo, T.; Nagata, I. Protocol of radiotherapy for glioblastoma according to the expression of HIF-1. Brain Tumor Pathol. 2004, 21, 1-6.
23. Ishikawa, H.; Sakurai, H.; Hasegawa, M.; Mitsuhashi, N.; Takahashi, M.; Masuda, N.; Nakajima, M.; Kitamoto, Y.; Saitoh, J.; Nakano, T. Expression of hypoxic-inducible factor 1alpha predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60, 513-521.
24. Semenza, G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29, 625-634.
25. Sinclair, W.K. Cyclic X-ray responses in mammalian cells in vitro. Radiat. Res. 1968, 33, 620-643.
26. Terasima, T.; Tolmach, L.J. Variations in several responses of HeLa cells to X-irradiation during the division cycle. Biophys. J. 1963, 3, 11-33.
27. Jiang, B.H.; Semenza, G.L.; Bauer, C.; Marti, H.H. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol 1996, 271, C1172-C1180.
28. Harada, H.; Inoue, M.; Itasaka, S.; Hirota, K.; Morinibu, A.; Shinomiya, K.; Zeng, L.; Ou, G.; Zhu, Y.; Yoshimura, M.; et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat. Commun. 2012, 3, 783.
29. Kizaka-Kondoh, S.; Tanaka, S.; Harada, H.; Hiraoka, M. The HIF-1-active microenvironment: An environmental target for cancer therapy. Adv. Drug Deliv. Rev. 2009, 61, 623-632.
30. Sobhanifar, S.; Aquino-Parsons, C.; Stanbridge, E.J.; Olive, P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005, 65, 7259-7266.
31. Zhu, Y.; Zhao, T.; Itasaka, S.; Zeng, L.; Yeom, C.J.; Hirota, K.; Suzuki, K.; Morinibu, A.; Shinomiya, K.; Ou, G.; et al. Involvement of decreased hypoxia-inducible factor 1 activity and resultant G(1)-S cell cycle transition in radioresistance of perinecrotic tumor cells. Oncogene 2012, doi:10.1038/onc.2012.223.
32. Evans, S.M.; Kachur, A.V.; Shiue, C.Y.; Hustinx, R.; Jenkins, W.T.; Shive, G.G.; Karp, J.S.; Alavi, A.; Lord, E.M.; Dolbier, W.R., Jr.; et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J. Nucl. Med. 2000, 41, 327-336.
33. Fujibayashi, Y.; Taniuchi, H.; Yonekura, Y.; Ohtani, H.; Konishi, J.; Yokoyama, A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 1997, 38, 1155-1160.
34. Koh, W.J.; Rasey, J.S.; Evans, M.L.; Grierson, J.R.; Lewellen, T.K.; Graham, M.M.; Krohn, K.A.; Griffin, T.W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 199-212.
35. Raleigh, J.A.; Calkins-Adams, D.P.; Rinker, L.H.; Ballenger, C.A.; Weissler, M.C.; Fowler, W.C., Jr.; Novotny, D.B.; Varia, M.A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 1998, 58, 3765-3768.
36. Vaupel, P.; Hockel, M.; Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox. Signal. 2007, 9, 1221-1235.
37. Vaupel, P.; Schlenger, K.; Knoop, C.; Hockel, M. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 1991, 51, 3316-3322.
38. Lord, E.M.; Harwell, L.; Koch, C.J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993, 53, 5721-5726.
39. Gross, M.W.; Karbach, U.; Groebe, K.; Franko, A.J.; Mueller-Klieser, W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int. J. Cancer 1995, 61, 567-573.
40. Dewhirst, M.W.; Ong, E.T.; Klitzman, B.; Secomb, T.W.; Vinuya, R.Z.; Dodge, R.; Brizel, D.; Gross, J.F. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat. Res. 1992, 130, 171-182.
41. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3, 177-182.
42. Pogue, B.W.; Paulsen, K.D.; O'Hara, J.A.; Wilmot, C.M.; Swartz, H.M. Estimation of oxygen distribution in RIF-1 tumors by diffusion model-based interpretation of pimonidazole hypoxia and eppendorf measurements. Radiat. Res. 2001, 155, 15-25.
43. Olive, P.L.; Banath, J.P.; Durand, R.E. The range of oxygenation in SiHa tumor xenografts. Radiat. Res. 2002, 158, 159-166.
44. Brown, J.M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol. 1979, 52, 650-656.
45. Chaplin, D.J.; Durand, R.E.; Olive, P.L. Acute hypoxia in tumors: Implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 1986, 12, 1279-1282.
46. Martinive, P.; Defresne, F.; Bouzin, C.; Saliez, J.; Lair, F.; Gregoire, V.; Michiels, C.; Dessy, C.; Feron, O. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: Implications for anticancer therapies. Cancer Res. 2006, 66, 11736-11744.
47. Cairns, R.A.; Kalliomaki, T.; Hill, R.P. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 2001, 61, 8903-8908.
48. Walenta, S.; Schroeder, T.; Mueller-Klieser, W. Metabolic mapping with bioluminescence: Basic and clinical relevance. Biomol. Eng. 2002, 18, 249-262.
49. Brown, J.M.; Giaccia, A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
50. Denko, N.C.; Fontana, L.A.; Hudson, K.M.; Sutphin, P.D.; Raychaudhuri, S.; Altman, R.; Giaccia, A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 2003, 22, 5907-5914.
51. Hockel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266-276.
52. Chen, C.; Pore, N.; Behrooz, A.; Ismail-Beigi, F.; Maity, A. Regulation of glut1 mRNA by hypoxiainducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276, 9519-9525.
53. Mathupala, S.P.; Rempel, A.; Pedersen, P.L. Glucose catabolism in cancer cells: Identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 2001, 276, 43407-43412.
54. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177-185.
55. Papandreou, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006, 3, 187-197.
56. Corn, P.G.; Ricci, M.S.; Scata, K.A.; Arsham, A.M.; Simon, M.C.; Dicker, D.T.; El-Deiry, W.S. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol. Ther. 2005, 4, 1285-1294.
57. Li, F.; Wang, Y.; Zeller, K.I.; Potter, J.J.; Wonsey, D.R.; O'Donnell, K.A.; Kim, J.W.; Yustein, J.T.; Lee, L.A.; Dang, C.V. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 2005, 25, 6225-6234.
58. Zhang, H.; Gao, P.; Fukuda, R.; Kumar, G.; Krishnamachary, B.; Zeller, K.I.; Dang, C.V.; Semenza, G.L. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11, 407-420.
59. Zhang, H.; Bosch-Marce, M.; Shimoda, L.A.; Tan, Y.S.; Baek, J.H.; Wesley, J.B.; Gonzalez, F.J.; Semenza, G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283, 10892-10903.
60. Fukuda, R.; Zhang, H.; Kim, J.W.; Shimoda, L.; Dang, C.V.; Semenza, G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129, 111-122.
61. Swietach, P.; Vaughan-Jones, R.D.; Harris, A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007, 26, 299-310.
62. Halestrap, A.P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 2004, 447, 619-628.
63. Bardos, J.I.; Ashcroft, M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays 2004, 26, 262-269.
64. Gottlieb, E.; Tomlinson, I.P. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat. Rev. Cancer 2005, 5, 857-866.
65. Lu, H.; Forbes, R.A.; Verma, A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 2002, 277, 23111-23115.
66. DeBerardinis, R.J. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. Genet. Med. 2008, 10, 767-777.
67. Levine, A.J.; Puzio-Kuter, A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330, 1340-1344.
68. Dang, C.V.; O'Donnell, K.A.; Zeller, K.I.; Nguyen, T.; Osthus, R.C.; Li, F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16, 253-264.
69. Shim, H.; Dolde, C.; Lewis, B.C.; Wu, C.S.; Dang, G.; Jungmann, R.A.; Dalla-Favera, R.; Dang, C.V. c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 1997, 94, 6658-6663.
70. Sears, R.; Leone, G.; DeGregori, J.; Nevins, J.R. Ras enhances Myc protein stability. Mol. Cell 1999, 3, 169-179.
71. Warburg, O. On the origin of cancer cells. Science 1956, 123, 309-314.
72. Dellian, M.; Helmlinger, G.; Yuan, F.; Jain, R.K. Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Br. J. Cancer 1996, 74, 1206-1215.
73. Kennedy, A.S.; Raleigh, J.A.; Perez, G.M.; Calkins, D.P.; Thrall, D.E.; Novotny, D.B.; Varia, M.A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 897-905.
74. Koshiji, M.; Kageyama, Y.; Pete, E.A.; Horikawa, I.; Barrett, J.C.; Huang, L.E. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004, 23, 1949-1956.
75. Dang, C.V.; Kim, J.W.; Gao, P.; Yustein, J. The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 2008, 8, 51-56.
76. Koshiji, M.; To, K.K.; Hammer, S.; Kumamoto, K.; Harris, A.L.; Modrich, P.; Huang, L.E. HIF-1α induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 2005, 17, 793-803.
77. Liu, Y.; Song, X.; Wang, X.; Wei, L.; Liu, X.; Yuan, S.; Lv, L. Effect of chronic intermittent hypoxia on biological behavior and hypoxia-associated gene expression in lung cancer cells. J. Cell. Biochem. 2010, 111, 554-563.
78. Zhang, X.; Kon, T.; Wang, H.; Li, F.; Huang, Q.; Rabbani, Z.N.; Kirkpatrick, J.P.; Vujaskovic, Z.; Dewhirst, M.W.; Li, C.Y. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1α. Cancer Res. 2004, 64, 8139-8142.
79. Hall, E.J. Radiobiology for the Radiologists, 4th ed.; J. B. Lippincott Company: Philadelphia, PA, USA, 1994.
80. Dewhirst, M.W.; Cao, Y.; Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 2008, 8, 425-437.
81. Zeng, L.; Ou, G.; Itasaka, S.; Harada, H.; Xie, X.; Shibuya, K.; Kizaka-Kondoh, S.; Morinibu, A.; Shinomiya, K.; Hiraoka, M. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 2008, 99, 2327-2335.
82. Wouters, B.G.; Brown, J.M. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 1997, 147, 541-550.